Murali Ramaswamy, MD
Pulmonary Disease · Greensboro, NCNPI 1013994797
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Boehringer Ingelheim at 54.4% of the total. Reporting peaked in 2019 at $6,648 and has fallen 83.2% since, to $1,118 in 2025. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $88.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$14K
- Genentech USA, Inc.$6K
- United Therapeutics Corporation$1K
- AstraZeneca$925
- GSK$849
- F. Hoffmann-la Roche AG$621
- plus $2K from 23 others
Across 599 payments — averaging $3290.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$632K
- United Therapeutics Corporation$614K
- Boehringer Ingelheim$374K
- Roche Products Limited$188K
- Astrazeneca UK Limited$82K
- Emergent Biosolutions Inc.$25K
- plus $56K from 4 others
What the payments were for
- Consulting fees$8,49133%
- Speaking & faculty fees$10,30840%
- Travel & lodging$1,9548%
- Food & beverage$5,10620%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 43 | $14,060 |
| Genentech USA, Inc. | 21 | $5,958 |
| United Therapeutics Corporation | 16 | $1,283 |
| AstraZeneca | 41 | $925 |
| GSK | 60 | $849 |
| F. Hoffmann-la Roche AG | 1 | $621 |
| Insmed, Inc. | 12 | $292 |
| Novartis | 18 | $278 |
| Genentech, Inc. | 3 | $201 |
| Amgen | 8 | $180 |
| Merck | 10 | $159 |
| Grifols USA, LLC | 7 | $155 |
| Actelion Pharmaceuticals US, Inc. | 6 | $106 |
| Mylan Specialty L.p. | 6 | $101 |
| Sanofi | 3 | $97 |
| Regeneron Healthcare Solutions, Inc. | 3 | $75 |
| Vifor Pharma, Inc. | 3 | $68 |
| Inogen, Inc. | 7 | $64 |
| Verona Pharma, Inc. | 3 | $58 |
| Mallinckrodt Hospital Products Inc. | 3 | $56 |
| Viatris Specialty LLC | 3 | $52 |
| AbbVie(2 entities) | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 4 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Shionogi Inc | 2 | $37 |
| Baxter Healthcare | 1 | $25 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Teleflex LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,867 in reported general payments places this provider in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 162 | $2,204,282 |
| Tyvaso DpiTreprostinil | 34 | $780,182 |
| Pirfenidone | 145 | $183,919 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $132,901 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 157 | $122,081 |
| Spiriva RespimatTiotropium Bromide | 132 | $89,015 |
| Dupixent PenDupilumab | 17 | $70,763 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 87 | $65,601 |
| Breo ElliptaFluticasone/Vilanterol | 88 | $41,645 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 41 | $28,642 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $24,844 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $19,682 |
| EliquisApixaban | 19 | $14,903 |
| DuleraMometasone/Formoterol | 44 | $14,447 |
| XareltoRivaroxaban | 14 | $10,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $14,060 | $2,321,938335 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $849 | $197,604310 claims |
| Grifols USA, LLCProlastin C | $155 | $132,90112 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $925 | $90,445152 claims |
| MerckDulera | $159 | $14,44744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Greensboro
- Michael WertGreensboro$412K
- Clinton YoungGreensboro$20K
- Robert ByrumGreensboro$18K
- Michael PritchettPinehurst$1.3M
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.